HC Wainwright Reaffirms “Buy” Rating for Femasys (NASDAQ:FEMY)

HC Wainwright restated their buy rating on shares of Femasys (NASDAQ:FEMY) in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.

Separately, Chardan Capital cut their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Stock Performance

NASDAQ FEMY opened at $1.65 on Wednesday. The business’s 50-day moving average price is $1.22 and its 200 day moving average price is $1.16. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. Femasys has a twelve month low of $0.86 and a twelve month high of $2.40. The company has a market capitalization of $37.78 million, a PE ratio of -2.04 and a beta of -2.81.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in Femasys during the fourth quarter worth about $45,000. Northern Trust Corp grew its holdings in shares of Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares during the period. Jane Street Group LLC acquired a new stake in Femasys during the 4th quarter worth approximately $30,000. Aljian Capital Management LLC purchased a new position in Femasys in the third quarter valued at approximately $27,000. Finally, Virtu Financial LLC acquired a new position in Femasys during the fourth quarter valued at approximately $25,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.